🔗 Permalink

Inventor profile of:

Yang LIU

City:

Potomac, Maryland

Country:

United States

Published Applications:

Last publication date:

2026-05-21

Top Assignees for applications by Yang LIU

The entities that hold a legal rights for patent applications filed by inventor LIU Yang:

ONCOC4, INC. 3 Rockville, MD United States
Children's National Medical Center 2 Washington, DC United States
University of Maryland ,Baltimore 1 Baltimore, MD United States
Oncoimmune, Inc. 1 Rahway, NJ United States
OncoImmune, Inc. 1 Rockville, MD United States
OncoImmune, Inc. 1 Wilmington, DE United States

Recent patent applications by LIU Yang

Yang LIU from Potomac, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-21

US20260139052A1

Chemistry; metallurgy

ANTI-CTLA-4 ANTIBODY DOSING REGIMENS

#2 | 2026-04-02

US20260092112A1

Chemistry; metallurgy

USE OF ANTI-CTLA-4 ANTIBODIES FOR TREATING ADENOID CYSTIC CARCINOMA

#3 | 2025-12-25

US20250387493A1

Human necessities

METHOD OF ABROGATING ANTI-DRUG ANTIBODY FORMATION, AND DRUG CONJUGATES FOR USE THEREIN

#4 | 2025-10-30

US20250333532A1

Chemistry; metallurgy

GLYCAN-SHIELDED CD24 EPITOPES AND USES THEREOF

#5 | 2025-08-14

US20250257117A1

Chemistry; metallurgy

MUTANT CD24 PROTEINS AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF CANCER

#6 | 2025-07-31

US20250243292A1

Chemistry; metallurgy

ANTI-CD24 COMPOSITIONS AND USES THEREOF

#7 | 2025-02-06

US20250043003A1

Chemistry; metallurgy

MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS

#8 | 2024-07-04

US20240218067A1

Chemistry; metallurgy

ANTI-SIGLEC COMPOSITIONS AND USES THEREOF

#9 | 2024-05-02

US20240139280A1

Human necessities

USE OF HIF-1-ALPHA INHIBITORS IN CANCER IMMUNOTHERAPY

#10 | 2024-02-01

US20240033317A1

Human necessities

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS FOR TREATING TP53-MUTATED ACUTE MYELOID LEUKEMIA

#11 | 2023-04-06

US20230108492A1

Chemistry; metallurgy

METHODS OF USE OF SOLUBLE CD24 FOR TREATING VIRAL PNEUMONIA

#12 | 2023-04-06

US20230103352A1

Human necessities

METHODS OF USE OF SOLUBLE CD24 FOR TREATING SARS-COV-2 INFECTION

#13 | 2022-08-18

US20220259286A1

Chemistry; metallurgy

CD80 and CD86 Binding Protein Compositions and Uses Thereof

#14 | 2022-08-18

US20220259285A1

Chemistry; metallurgy

CD80 and CD86 binding protein compositions and uses thereof

#15 | 2019-10-10

US20190307841A1

Human necessities

Use of CD24 for lowering low-density lipoprotein cholesterol levels

InventorID:

5493491 ⎘